John W Childs

Director

John W Childs (Director) filed 5 Form 4 reports in the trailing twelve months (4 purchases, 1 sale, 2 filed past the two-business-day deadline), most often in BHVN. Across 2 priced purchase filings, the average 21-session return was +37.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $25.0M of BHVN (3,333,333 sh × $7.50, as filed), executed Nov 13 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+37.0%

avg across 2 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+27.3%

same 2 filings, from disclosure

Filings, ttm

4 buys · 1 sells · 2 late

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$46.6M

shares × price, as filed

Last traded

Aug 12

Filed Aug 14

Median ADV $79.0M across their filed names

Impact on $10,000 · 12M

$16,216 (+62.2%)

S&P 500 $11,725 (+17.2%) · 44.9 pts ahead

John W Childs S&P 500

Compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $41.9M Sells $10.7M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 3 filings Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names

BHVN BHVN BHVN · 6 buys · 0 sells 6 filings MANE

Veradermics, Incorporated MANE · 2 buys · 1 sell 3 filings

Recent filings

BHVNPURCHASE Biohaven Ltd. View filing → $3.0M
73,170 sh × $41.00
Exec Apr 22 2024
Filed Mar 5 2025 · 5:30 PM ET †